2022 Influenza Vaccine Production & Distribution Market Report

Part 3 Of 3

Flu Vaccine Report

Flu vaccination rates for the 2021-2022 flu season decreased compared to the prior flu season. Both adults and children in the 2021-2022 flu season experienced the lowest vaccination coverage since the 2018-2019 flu season. As vaccination coverage decreases, the spread of respiratory illnesses and infections is rising in the U.S. The 2022 HIDA Influenza Vaccine Report’s third of three preview reports provides insights into overall flu vaccination coverage including:

  • 74% of U.S. adults 65 and older received their flu vaccine in the 2021-2022 flu season.
  • 67% of children received their flu vaccination at the doctor’s office in the 2021-2022 flu season.
  • Respiratory syncytial virus (RSV) associated hospitalizations in the 2022-2023 RSV season are the highest in the past five RSV seasons.

Free for members; members only. To purchase a PDF license for your entire team allowing unlimited distribution within your company, please email hida@hida.org.

Members: Click below to log in and download the report as a PDF.

Download Part 3


Part 2 Of 3

Flu Vaccine Report

The 2021-2022 U.S. flu season experienced the lowest influenza vaccine coverage since 2017. Low flu activity, vaccine hesitancy, and COVID-19 concerns contributed to the decline. As vaccine coverage declined, pediatric deaths rose from one death in the 2020-2021 season to 34 deaths in the 2021-2022 flu season. The 2022 HIDA Influenza Vaccine Report’s second of three preview reports provides insights into the previous flu season, including:

  • 174.7 million doses of the influenza vaccine were distributed during the 2021-2022 flu season, down 19.4 million from the prior season.
  • A 16% interim vaccine effectiveness was estimated for the 2021-2022 flu vaccine, the lowest vaccine effectiveness since 2004.
  • Ninety-percent of people hospitalized with the flu in recent flu seasons had at least one underlying chronic health condition.

Free for members; members only. To purchase a PDF license for your entire team allowing unlimited distribution within your company, please email hida@hida.org.

Members: Click below to log in and download the report as a PDF.

Download Part 2


Part 1 Of 3

Flu Vaccine Report

The U.S. saw an extended 2021-2022 flu season, continuing through June 2022. States lifting COVID-19 restrictions, children’s return to in-person learning, and employees returning to the office all contributed to the prolonged flu season. As the Southern Hemisphere reports the highest flu rates since 2017, the U.S. prepares for a potentially difficult 2022-2023 flu season. The 2022 HIDA Influenza Vaccine Report’s first of three preview reports provides insights into the upcoming flu season including:

  • An estimated 171.5 million doses of the influenza vaccine will be manufactured for the upcoming season.
  • Influenza A accounted for 96.7% of influenza hospitalizations last season.
  • A higher dosage flu vaccine has been recommended for adults 65 and older.

Free for members; members only. To purchase a PDF license for your entire team allowing unlimited distribution within your company, please email hida@hida.org.

Members: Click below to log in and download the report as a PDF.

Download Part 1

You May Also Like:
/am/images/4Q/research/vaccine-market-report-webcard.jpg
Market Insights
Market Report
Vaccine Market Report
Read More >
/am/images/4Q/advocacy/optimizing-med-supplies-during-covid-vaccination-infographic-2021-webcard.jpg
Pandemic Preparedness
Infographic
Optimizing Use Of Medical Supplies During The COVID-19 Vaccination Effort
Read More >
/am/images/4Q/resources/covid-19-vaccine-comparison-500x400.jpg
Vaccines, COVID-19
Vaccine Comparison
Comparison Of Leading COVID-19 Vaccines For U.S. Distribution
Read More >

Contact:

Chandler Mobley

Chandler Mobley, MPH
Manager, Research & Market Insights
703-838-6113
mobley@hida.org